Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/rmdopen-2017-000533 http://scihub22266oqcxt.onion/10.1136/rmdopen-2017-000533 C6045702!6045702!30018796     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       RMD+Open 2018 ; 4 (1): ä Nephropedia Template TP {{tp|p=30018796|t=2018. Haematopoietic stem cell transplantation in systemic sclerosis |pdf=|usr=}}{{30018796}} gab.com Text Haematopoietic stem cell transplantation in systemic sclerosis JO: RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=30018796 #FOAvip Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, sustained improvement of forced vital capacity with improvements in skin thickening, vasculopathy and health-related quality of life, in contrast to a clinical decline in standard of care control groups. These benefits, however, must be weighed against the increased risk of transplant-related mortality. Further, with disease progression, severe extensive internal organ involvement and damage ensues, constituting an exclusion criterion for safety reasons, leaving a limited window whereby patients with SSc are eligible for HSCT. Although autologous HSCT offers the possibility of drug-free remission, relapse can occur, requiring re-initiation of disease modifying antirheumatic drugs. HSCT is also associated with secondary autoimmune diseases and gonadal failure. HSCT should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement. Twit Text FOAVip Haematopoietic stem cell transplantation in systemic sclerosis ????RMD Open http://www.kidney.de/pget.php?&tw=1&pmid=30018796 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30018796 #FOAvip English Wikipedia <ref>{{Cite pmid|30018796}}</ref> Haematopoietic stem cell transplantation in systemic sclerosis #MMPMID30018796 Walker UA; Saketkoo LA; Distler O RMD Open 2018[]; 4 (1): ä PMID30018796show ga Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, sustained improvement of forced vital capacity with improvements in skin thickening, vasculopathy and health-related quality of life, in contrast to a clinical decline in standard of care control groups. These benefits, however, must be weighed against the increased risk of transplant-related mortality. Further, with disease progression, severe extensive internal organ involvement and damage ensues, constituting an exclusion criterion for safety reasons, leaving a limited window whereby patients with SSc are eligible for HSCT. Although autologous HSCT offers the possibility of drug-free remission, relapse can occur, requiring re-initiation of disease modifying antirheumatic drugs. HSCT is also associated with secondary autoimmune diseases and gonadal failure. HSCT should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement. äHaematopoietic stem cell transplantation in systemic sclerosis (epmc).pdf DeepDyve Pubget Overpricing